Sanofi and Regeneron report positive Phase III data from atopic dermatitis trial

Sanofi and Regeneron Pharmaceuticals have reported positive results from the Phase III clinical trial (CAF É ) of Dupixent (dupilumab) to treat moderate-to-severe atopic dermatitis (AD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news